Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Genevieve DallCassandra J VandenbergKsenija NesicGayanie RatnayakeWenying ZhuJoseph H A VissersJustin BedőJocelyn PeningtonMatthew J WakefieldDamien KeeAmandine CarmagnacRatana LimKristy Shield-ArtinBriony MilesiAmanda LobleyElizabeth L KyranEmily O'GradyJoshua TramWarren ZhouDevindee NugawelaKym Pham StewartReece CaldwellLia PapadopoulosAshley P NgAlexander DobrovicStephen B FoxOrla McNallyJeremy D PowerTarek MeniawyTeng Han TanIan M CollinsOliver KleinStephen BarnettInger OlesenAnne HamiltonOliver HofmannSean GrimmondAnthony T PapenfussClare L ScottHolly E BarkerPublished in: Journal of experimental & clinical cancer research : CR (2023)
Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.